Literature DB >> 6282480

Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy.

P G Harper, M B Dally, D M Geddes, S G Spiro, J F Smyth, R L Souhami.   

Abstract

Thirty-eight patients with small cell carcinoma of the bronchus resistant to initial chemotherapy with cyclophosphamide methotrexate and CCNU, were treated with VP16-213 alone in a dose of 120 mg/m2 i.v. on days 1, 3, and 5 every 3 weeks. Twelve patients died before three courses of treatment. In 26 patients who received three or more courses only one, transient partial response occurred. One or more components of the initial chemotherapy seems to confer resistance to the action of VP16-213 in this disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282480     DOI: 10.1007/bf00254544

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

Authors:  M H Cohen; L E Broder; B E Fossieck; D C Ihde; J D Minna
Journal:  Cancer Treat Rep       Date:  1977 May-Jun

2.  Chemotherapy of small cell carcinoma of the lung with V.P. 16-213.

Authors:  R D Tucker; A Ferguson; C Van Wyk; R Sealy; R Hewitson; W Levin
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

3.  VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

Authors:  R T Eagan; D T Carr; S Frytak; J Rubin; R E Lee
Journal:  Cancer Treat Rep       Date:  1976-07

4.  Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).

Authors:  M Hansen; F Hirsch; P Dombernowsky; H H Hansen
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

5.  Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.

Authors:  N I Nissen; T F Pajak; L A Leone; C D Bloomfield; B J Kennedy; R R Ellison; R T Silver; R B Weiss; J Cuttner; G Falkson; F Kung; P R Bergevin; J F Holland
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

Review 6.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  6 in total
  4 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Chemotherapy in non-small cell bronchial carcinoma.

Authors:  R Souhami
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

4.  An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

Authors:  L A Doyle; D D Ross; J V Ordonez; W Yang; Y Gao; Y Tong; C P Belani; J C Gutheil
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.